EW
Edwards Lifesciences Corp
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Best Orthopedic Devices Stocks 2026 →
Edwards Lifesciences (EW) Stock: Buy, Sell, or Hold?
$104.01
-0.70 (-0.67%)
▼
5d:
+9.27%
30d:
+20.4%
90d:
+11.78%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (18%)
Quality Score
42/100
Position
EXTENDED
30-Day Fair Range
$85.08 – $97.00
Position: EXTENDED
Forward P/E & Valuation
30.6x
STRETCHED
vs 26.4x historical avg
Wall Street Target
$111.64
+7.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$87.90 / $105.37
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: EW shows conflicting indicators. Wait for confirmation before entering.
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Nov 2, 2026 at $93.26 · last confirmed Nov 9, 2026
Strength: 6.6/10
Get Alerted When EW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$127.33
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$79.06
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EW is currently trading at $104.01, which is considered extended relative to its 30-day fair value range of $85.08 to $97.00. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.6) compared to its historical average (26.4). At these levels, the market is pricing in 5.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EW is in a uptrend. The price is approaching resistance at $105.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EW scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EW is in a uptrend. The price is approaching resistance at $105.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EW scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$85.08 -
$97.00
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
18.1%
Trading Range & Key Levels
30-Day Trading Range
$85.08 -
$97.00
Current vs Trading Range
EXTENDED
Support Level
$87.90
Resistance Level
$105.37
Current Trend
Uptrend
Technical data as of
Nov 10, 2026
Protect Your Profits
EW is technically overbought (RSI 77). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range (+7.2% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($111.64)
- NEUTRAL: Trading at premium valuation - market expects 5.1% growth which is achievable
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
30.57
Wall Street Target
$111.64
(+7.3%)
Revenue Growth (YoY)
10.5%
Earnings Growth (YoY)
6.7%
Profit Margin
15.3%
Valuation Premium vs History
+5.1% premium
PE vs Historical
30.6 vs 26.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.1%
(market-implied from PE analysis)
1-Year Target
$109.31
(+5%)
2-Year Target
$114.89
(+11%)
3-Year Target
$120.75
(+16%)
3-Yr Target (if PE normalizes)
(PE: 31→26)
PE COMPRESSION
$104.27
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.6, Growth: 12.9%)
$149.76
(+44%)
Base:
(SPY PE: 19.9, Growth: 12.9%)
$97.29
(-7%)
Bear:
(PE: 16.9, Growth: 12.9%)
$82.70
(-21%)
📈
Valuation based on Current Earnings
Forward PE: 30.12 | Forward EPS (Implied): $3.45
Bull Case
$125.59
(+21%)
Analyst growth 15.0%, PE expands to 31.6
Base Case
$104.01
(0%)
Market implied 0.0%, PE stable at 30.1
Bear Case
$79.57
(-24%)
Severe decline -15.0%, PE contracts to 27.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share EW Analysis
Share this live EW analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (EW)
Bearish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 2, 2026
Daily AI digest
AI Retail Discussion Summary:
Edwards Lifesciences announced positive results from the Progress trial of its TAVR system, showing superiority over clinical surveillance for moderate aortic stenosis patients with at-risk features.
Key Retail Themes:
Edwards Lifesciences TAVR trials
Superiority of TAVR over clinical surveillance
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 10, 2026 9:28 PM ET
Data refreshes hourly during market hours. Next update: 10:28 PM
Data refreshes hourly during market hours. Next update: 10:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$98 | 47 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$119 | 37 SELL |
|
SYK
Stryker Corporation |
STRONG BUY
30 analysts |
$340 | 31 SELL |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
22 analysts |
$88 | 33 SELL |
|
CATX
Perspective Therapeutics… |
STRONG BUY
14 analysts |
$11 | 51 HOLD |
Advanced EW Option Strategies
Professional options setups generated by AI based on today's EW price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive EW Research Pages
